Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. Burotto M, Chiou VL, Lee J-M, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014. https://doi.org/10.1002/cncr.28864.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002. https://doi.org/10.1038/nature00766.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011. https://doi.org/10.1056/NEJMoa1103782.
4. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019. https://doi.org/10.1056/NEJMoa1904059.
5. US FDA. FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600e mutation. Case medical research. 2017. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-dabrafenib-and-trametinib-combination-metastatic-nsclc-braf-v600e. [Accessed 3 Jul 2024].